These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 17123806)

  • 1. Osteopontin promotes pathologic mineralization in articular cartilage.
    Rosenthal AK; Gohr CM; Uzuki M; Masuda I
    Matrix Biol; 2007 Mar; 26(2):96-105. PubMed ID: 17123806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transglutaminase activity in aging articular chondrocytes and articular cartilage vesicles.
    Rosenthal AK; Derfus BA; Henry LA
    Arthritis Rheum; 1997 May; 40(5):966-70. PubMed ID: 9153560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Up-regulated expression of cartilage intermediate-layer protein and ANK in articular hyaline cartilage from patients with calcium pyrophosphate dihydrate crystal deposition disease.
    Hirose J; Ryan LM; Masuda I
    Arthritis Rheum; 2002 Dec; 46(12):3218-29. PubMed ID: 12483726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transglutaminase contributes to CPPD crystal formation in osteoarthritis.
    Heinkel D; Gohr CM; Uzuki M; Rosenthal AK
    Front Biosci; 2004 Sep; 9():3257-61. PubMed ID: 15353354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dexamethasone promotes calcium pyrophosphate dihydrate crystal formation by articular chondrocytes.
    Fahey M; Mitton E; Muth E; Rosenthal AK
    J Rheumatol; 2009 Jan; 36(1):163-9. PubMed ID: 19132782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cartilage intermediate layer protein expression in calcium pyrophosphate dihydrate crystal deposition disease.
    Yamakawa K; Iwasaki H; Masuda I; Ohjimi Y; Honda I; Iyama K; Shono E; Naito M; Kikuchi M
    J Rheumatol; 2002 Aug; 29(8):1746-53. PubMed ID: 12180739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcium pyrophosphate crystal deposition in hyaline cartilage. Ultrastructural analysis and implications for pathogenesis.
    Pritzker KP; Cheng PT; Renlund RC
    J Rheumatol; 1988; 15(5):828-35. PubMed ID: 2845077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of chondrocyte production of extracellular inorganic pyrophosphate.
    Costello JC; Ryan LM
    Curr Opin Rheumatol; 2004 May; 16(3):268-72. PubMed ID: 15103256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transglutaminase participates in the incorporation of latent TGFbeta into the extracellular matrix of aging articular chondrocytes.
    Le M; Gohr CM; Rosenthal AK
    Connect Tissue Res; 2001; 42(4):245-53. PubMed ID: 11913769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contribution of calcium-containing crystals to cartilage degradation and synovial inflammation in osteoarthritis.
    Liu YZ; Jackson AP; Cosgrove SD
    Osteoarthritis Cartilage; 2009 Oct; 17(10):1333-40. PubMed ID: 19447216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upregulation of ANK protein expression in joint tissue in calcium pyrophosphate dihydrate crystal deposition disease.
    Uzuki M; Sawai T; Ryan LM; Rosenthal AK; Masuda I
    J Rheumatol; 2014 Jan; 41(1):65-74. PubMed ID: 24293574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extracellular matrix changes regulate calcium crystal formation in articular cartilage.
    Kalya S; Rosenthal AK
    Curr Opin Rheumatol; 2005 May; 17(3):325-9. PubMed ID: 15838245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formation of calcium pyrophosphate crystals: biologic implications.
    Rosenthal AK
    Curr Opin Rheumatol; 2000 May; 12(3):219-22. PubMed ID: 10803752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histologic localization of lipid in the articular tissues in calcium pyrophosphate dihydrate crystal deposition disease.
    Ohira T; Ishikawa K; Masuda I; Yokoyama M; Honda I
    Arthritis Rheum; 1988 Aug; 31(8):1057-62. PubMed ID: 2457374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanobiological implications of articular cartilage crystals.
    Carlson AK; McCutchen CN; June RK
    Curr Opin Rheumatol; 2017 Mar; 29(2):157-162. PubMed ID: 27941391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A clinical study of calcium pyrophosphate dihydrate crystal deposition disease].
    Ogata M
    Nihon Seikeigeka Gakkai Zasshi; 1985 Aug; 59(8):819-34. PubMed ID: 3003215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of calcium pyrophosphate dihydrate crystal formation in articular cartilage vesicles and cartilage by phosphocitrate.
    Cheung HS; Kurup IV; Sallis JD; Ryan LM
    J Biol Chem; 1996 Nov; 271(45):28082-5. PubMed ID: 8910421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histochemical localization of calcium with potassium pyroantimonate in the articular tissues in calcium pyrophosphate dihydrate crystal deposition disease.
    Ohira T; Ishikawa K
    Clin Orthop Relat Res; 1991 Mar; (264):286-94. PubMed ID: 1705190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promotion of articular cartilage matrix vesicle mineralization by type I collagen.
    Jubeck B; Gohr C; Fahey M; Muth E; Matthews M; Mattson E; Hirschmugl C; Rosenthal AK
    Arthritis Rheum; 2008 Sep; 58(9):2809-17. PubMed ID: 18759309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A histologic and immunohistochemical study of calcium pyrophosphate dihydrate crystal deposition disease.
    Masuda I; Ishikawa K; Usuku G
    Clin Orthop Relat Res; 1991 Feb; (263):272-87. PubMed ID: 1993383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.